CHEK2 and infection: Treatment with Chk2 inhibitor II, which prevented the activation of Chk2 (as evidenced by the loss of Chk2 with an altered mobility; Figure 2D, panel c, compare lanes 2 and 3), prevented the reduction in CDC25A levels observed following MVM infection of either para-synchronous (Figure 2D, panel d, compare lanes 2 to 3), or asynchronous (data not shown) A9 cells, without affecting the levels of the related CDC25C protein (Figure 2D, panel e).